Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPX-100
- Development stage
- Phase 2
- Lead developer
- OrthoTrophix
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intraarticular
01
Overview
TPX-100 is a 23-amino acid peptide derived from matrix extracellular phosphoglycoprotein (MEPE). It is being developed as a first-in-class disease-modifying osteoarthritis drug (DMOAD) for intra-articular injection. TPX-100 has been shown to induce articular cartilage formation and increase type II collagen in preclinical models, and in clinical trials it demonstrated significant improvements in knee function, pain reduction, and delayed progression of pathological bone shape changes compared to placebo. The mechanism of action involves stimulation of aggrecan, collagen production, and integrin pathways. Developed by OrthoTrophix, TPX-100 is currently in phase II clinical development for osteoarthritis.
- Other names
- Dentonin
02
Targets
ACAN (Aggrecan core protein)Neuraminidase
Beyond the preview
Go deeper on TPX-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPX-100.